/daily ·24 JUL 2026 ·FRIDAY ·2 MIN READ ·5 STORIES

The Drug That Lost Its Heart

Eli Lilly's retatrutide delivered record weight-loss numbers but failed the cardiovascular endpoint. The FDA's advisory panel opened the door to compounding of BPC-157, KPV, and TB-500. A quieter-than-usual Friday for the field.

01 / The Day

FRIDAY 24 JUL 2026, ranked

Retatrutide achieves 22.6% weight loss in Phase 3 but misses cardiovascular endpoint

Eli Lilly's Phase 3 trial of retatrutide — a triple GIP/GLP-1/glucagon agonist — showed 22.6% body weight reduction at the highest dose over 48 weeks, the largest Phase 3 obesity trial result to date. The drug did not demonstrate statistically significant reduction in major adverse cardiovascular events, narrowing its approvability pathway.

Why it mattersCardiovascular outcome data is the commercial multiplier that turned semaglutide into a blockbuster; without it, retatrutide competes on weight loss alone, which is a narrower and more contested market.

01 statnews.com↗

FDA advisory panel votes to allow compounding of BPC-157, KPV, and TB-500

An FDA advisory committee recommended authorizing compounding pharmacies to manufacture BPC-157, KPV, and TB-500 — three peptides with significant popularity in longevity and sports-recovery communities but limited large-trial evidence — marking a shift in the FDA's historic resistance to classifying them as bulk drug substances.

Why it mattersAuthorization for compounding substantially expands access while removing these compounds from the legal grey zone where they have operated, changing both their supply chain and their research pathway.

02 statnews.com↗

Gut microbiome composition predicts biological aging rate as measured by epigenetic clocks

A study identified specific gut microbial species whose relative abundance correlates with the rate of biological aging as measured by established epigenetic clocks, with particular microbial signatures tracking with either accelerated or decelerated aging pace, independent of chronological age.

Why it mattersA microbiome-to-epigenetic-clock correlation gives potential mechanistic specificity to the gut-health-longevity relationship, which has until now been largely observational and without clear direction of causality.

03 fightaging.org↗

Nature Aging perspective positions TERT as master integrator across multiple aging pathways

A new perspective in Nature Aging argues that TERT — the catalytic subunit of telomerase — functions beyond telomere maintenance to regulate gene expression, mitochondrial function, and inflammatory signaling, positioning it as a convergence point for multiple established aging pathways and a candidate therapeutic target.

Why it mattersA unifying framework for disparate aging mechanisms would focus research investment rather than distribute it across disconnected targets — and TERT's molecular biology is already well-mapped, shortening the distance to therapeutic candidates.

04 nature.com↗

Autophagy surge protects young kidneys from toxin injury but fails in aged tissue

A study found that young mice respond to nephrotoxic injury by rapidly upregulating autophagy through TFEB activation, clearing damaged proteins and preventing acute kidney failure. Aged mice do not mount this response; restoring TFEB activity in older animals partially recovered the protective effect.

Why it mattersIt gives mechanistic specificity to why aged organs are more vulnerable to acute injury, and identifies TFEB-mediated autophagy as a specific molecular lever that could be tested as a therapeutic target.

05 lifespan.io↗

Be subscriber #012 the weekly ten, every friday by email · no spam · unsubscribe anytime

Past days

The Daily Archive

/FRI 31 JULBlood proteins predict liver disease 16 years early /WED 29 JULWednesday, 29 July — Clocks, guts, heat /MON 27 JULFDA Splits the Peptide Vote, Salk Finds Zombie Cells' Weakness, and GBD Says Healthy Years Aren't Keeping Pace /FRI 24 JULThe Drug That Lost Its Heart /WED 22 JULBlood, bone, and the morbidity gap /FRI 17 JULFriday in Longevity: Clocks, Fat, and Immune Decay /WED 15 JULSenescent terrain /MON 13 JULLecanemab under the skin /FRI 10 JULLongevity | Jul 10 2026: Gut, Senescence, Epigenetics /WED 08 JULDrugs remapped to aging hallmarks, ovarian aging reversed, and a 50% molecular gap /MON 06 JULCentenarian chemistry, sleeping circuits, and reprogrammed eyes /FRI 03 JULOvaries, progenitors, and oxygen /WED 01 JULTelomere signals, proteomic clocks, and faster biological aging /MON 29 JUNMonday, June 29 — Longevity /FRI 26 JUNWhen you sleep matters; what your cells do with miscopied RNA also matters /TUE 23 JUNGenes, Clocks, and GLP-1s /MON 22 JUNMonday: Senescent cells, climbing clocks, and late-life gene therapy /FRI 19 JUNLongevity — June 19, 2026 /WED 17 JUNClocks, Loops, and One Very Productive Bacteria /MON 15 JUNReprogramming closes first human trial; circadian link firms /FRI 12 JUNAging regimes, borrowed sleep, and a race to measure biological age